Phase III study of Saxenda in adolescent obesity published in New England Journal of Medicine.- Novo Nordisk
Related news and insights
Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Wegovy for chronic weight management in adults with obesity.
Results from the STEP 5 phase IIIb trial, presented by Novo Nordisk at the Obesity Week 2021 interactive congress, showed that adults treated with Wegovy (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period.
Novo Nordisk announced that the FDA has approved Wegovy (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI greater than 30 kg/m2) or overweight (initial BMI greater than 27 kg/m2) with at least one weight-related comorbidity.